


# Vaccine-induced antibodies still potent against more contagious SARS-CoV-2 variant

23 March 2021, by Quinn Eastman



A, Data from 20 patients with acute COVID-19 infection (5-19 days after symptom onset). B, Data from 20 convalescent COVID-19 individuals (32-94 days after symptom onset). C, Data from 14 healthy individuals (aged 18-55 years) who received the Moderna (mRNA-1273) vaccine, 100- $\mu$ g dose, on day 14 (postsecond dose). The geometric mean titers (GMTs) with 95% CI are shown for samples against the A.1, B.1, B.1.1.7, and N501Y variants. The horizontal dashed lines indicate the limit of detection (FRNT<sub>50</sub> GMT = 20). Statistical significance was determined with the Kruskal-Wallis test to compare GMTs between the variants, followed by the Dunn's multiple comparison post hoc test. For A (acutely infected patients) and B (convalescent individuals), no comparisons were statistically significant. For C (vaccinated individuals), significant differences were found for variant A.1 vs B.1 (P

APA citation: Vaccine-induced antibodies still potent against more contagious SARS-CoV-2 variant (2021, March 23) retrieved 8 October 2022 from <https://medicalxpress.com/news/2021-03-vaccine-induced-antibodies-potent-contagious-sars-cov-.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*